The Abbott Nutrition plant linked to the shortage of baby formula has struck a deal to resume operations within two weeks, according to the US Food and Drug Administration.
Abbott entrered a consent decree with the FDA on Monday, which if court-approved sets out the steps the company needs to carry out to resume production at the Michigan factory.
